This article discusses the synthesis of the complex compound [Cu(L1)2(m-pyr)2] .2H2O (L1-ibuprofen, m-pyr methylpyridine) and its crystal
structure. The substance obtained as the main ligand is ibuprofen ((RS)-2-(4-isobutylphenyl)-propionic acid) and auxiliary ligand 4-ethylpyridine, and the structure of the complex compound was determined by infrared (IR) spectroscopy, scanning electron microscope-energy dispersive analysis (SEMEDX), its stability was studied by the TG-DSK method, and the parameters related to the single crystal of the complex compound were studied using X-ray structure analysis (XRD) methods. In the obtained coordination compound, the coordination number of copper is equal to 6, and in the formation of the complex compound, two places are occupied by the ibuprofen molecule, two more places are occupied by the 4-methylpyridine molecule, and the remaining places are occupied by the water molecule. (RS)-2-(4-isobutylphenyl)-propionic acid as a monodentate ligand containing an oxygen atom is important because it forms stable complex compounds with most intermediate metal ions. Antibacterial activity of newly obtained complex compounds was determined in vitro in strains of gram-positive bacteria Staphylococcus aureus, Bacillus subtilis, gram-negative bacteria Escherichia coli and Candida albicans. As a result of the conducted research, the antibacterial activity of newly obtained complex compounds has been significantly increased compared to ibuprofen, besides, the biological activity of mixed-ligand complex compounds compared to monoligand metallocomplexes has been proved.